HIV Compartments and Viral Rebound During Treatment Interruption
One of the main challenging characteristics of HIV is its extensive genetic diversity. This diversity is apparent across geography as represented by differing clades, but on a smaller scale exists within an individual. Viral phylogenetic studies within the same individual have shown diversity and divergence of the HIV virus in the multiple cell types and tissues analyzed. These subpopulations are known as viral quasispecies (Blackard 2012). The local environment present in the tissues influences the evolution of the quasispecies and subsequently impacts cellular tropism (i.e., higher affinity to macrophages from brain-derived virus), affects the response to antiretroviral therapy (ART), and ultimately, could affect eradication strategies.
A compartment has been defined as an anatomical site in which the virus is present, and there is limited exchange of viral genetic information with other sites and may contain compartment-specific viral sequences (Eisele and Siliciano 2012)...
KeywordsBacterial Vaginosis Follicular Dendritic Cell Viral Rebound Latent Reservoir Structure Treatment Interruption
- Kearney MF, Wiegand A, Shao W, Coffin JM, Mellors JW, et al. Origin of rebound plasma HIV includes cells with identical proviruses that are transcriptionally active before stopping antiretroviral therapy. J Virol. 2015;90(3):1369–76.Google Scholar
- Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS (London, England). 2016;30(3):343–53.Google Scholar
- Rothenberger MK, Keele BF, Wietgrefe SW, Fletcher CV, Beilman GJ, et al. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc Natl Acad Sci USA. 2015;112(10):E1126–34.Google Scholar
- Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, et al. Post-treatment HIV controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog. 2013;9(3):e1003211.CrossRefPubMedPubMedCentralGoogle Scholar